Jennifer Ruddock | Investor Relations |
Howard Robin | President & Chief Executive Officer |
Gil Labrucherie | Chief Financial Officer |
Steve Doberstein | Head of R&D |
Dr. Jonathan Zalevsky | Chief Scientific Officer |
Dr. Mary Tagliaferri | Chief Medical Officer |
Chris Shibutani | Cowen & Company |
Robert Hazlett | BTIG |
Tyler Van Buren | Piper Jaffray |
Jessica Fye | JPMorgan |
Difei Yang | Mizuho Securities |
Asthika Goonewardene | Bloomberg Intelligence |
Andy Hsieh | William Blair & Company |
Good day, ladies and gentlemen and welcome to the Nektar Therapeutics Q3 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call maybe recorded. I would now like to introduce your host for today's conference, Ms.